About us

Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic and fibrotic diseases and fight cancer. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.